Satoh Akira, Satoh Takehiko, Kaneta Hiroyuki, Kato Takumi, Notani Ken-Ichi, Kitagawa Yoshimasa
Oral Diagnosis and Medicine, Dept.of Oral Pathobiological Science, Hokkaido University Graduate School of Dental Medicine.
Gan To Kagaku Ryoho. 2007 May;34(5):749-51.
The patient is a 65-year-old man, who underwent curative resection for maxillary sinus carcinoma after chemoradiation. Lung metastases were observed two months following resection, and were treated with S-1 at a dose of 120 mg/day. One course of the S-1 administration regimen consisted of 2 weeks and a 1-week interval. The patient achieved long survival for 527 days with no adverse reaction. Therefore, this treatment on an outpatient basis greatly contributed to his quality of life. We consider S-1 as a first-line anti-cancer drug for tumor dormancy therapy.
该患者为一名65岁男性,在接受放化疗后接受了上颌窦癌根治性切除术。切除术后两个月发现肺部转移,随后接受S-1治疗,剂量为120毫克/天。S-1给药方案的一个疗程为2周,间隔1周。患者实现了527天的长期生存,且无不良反应。因此,这种门诊治疗对他的生活质量有很大帮助。我们认为S-1是肿瘤休眠治疗的一线抗癌药物。